Clinical Ethics 3 (3):145-148 (2008)

The Human Fertilisation and Embryology Authority have recently granted a licence to perform preimplanation genetic diagnosis (PGD) for the homozygous form of familial hypercholesterolaemia (FH), explicitly excluding its use for the heterozygous form. The grounds for such decisions centre on how serious a condition is thought to be as well as on the availability of effective treatment, and decisions are made on a case-by-case basis. The case for licensing homozygous FH is discussed and compared with other cases, and the case for making a distinction between PGD for homozygous and heterozygous FH is also examined. Testing for homozygous FH raises difficult issues of non-disclosure of results for heterozygous FH. Fears that this decision may represent a ‘slippery slope’ to more widespread testing are argued to be overstated
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1258/ce.2008.008021
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 58,769
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Preimplantation Genetic Diagnosis and the 'New' Eugenics.D. S. King - 1999 - Journal of Medical Ethics 25 (2):176-182.
Jewish Perspectives on the Use of Preimplantation Genetic Diagnosis.Mark Popovsky - 2007 - Journal of Law, Medicine and Ethics 35 (4):699-711.
Is There a Duty to Share Genetic Information?S. Matthew Liao - 2009 - Journal of Medical Ethics 35 (5):306-309.


Added to PP index

Total views
7 ( #1,015,613 of 2,425,353 )

Recent downloads (6 months)
3 ( #248,061 of 2,425,353 )

How can I increase my downloads?


My notes